{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:38:48Z","timestamp":1790401128895,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaci.2025.10.031","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T09:05:55Z","timestamp":1763111155000},"page":"442-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-4256","authenticated-orcid":false,"given":"R. Sharon","family":"Chinthrajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Sicherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Shreffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"Burk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Keet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayantani","family":"Sindher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Scurlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Lanser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica W.","family":"Hui-Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Vickery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idil D.","family":"Ezhuthachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Andrew","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Spergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Brown-Whitehorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dantzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ligueros-Saylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tassinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ozanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine","family":"Huckabee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Yovetich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adora","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Brittain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkis","family":"Togias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.10.031_bib1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.10.031_bib2","unstructured":"US Food and Drug Administration. XOLAIR (omalizumab) for injection, for subcutaneous use [package insert]."},{"key":"10.1016\/j.jaci.2025.10.031_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.anai.2022.01.037","article-title":"Peanut cross-contamination in randomly selected baked goods","volume":"128","author":"Miller","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.10.031_bib4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaip.2022.10.022","article-title":"Retail food equivalents for post-oral immunotherapy dosing in the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food-Allergic Children and Adults (OUtMATCH) clinical trial","volume":"11","author":"Groetch","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.10.031_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2025.10.031_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eclinm.2018.12.006","article-title":"A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals","volume":"7","author":"Andorf","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaci.2025.10.031_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaci.2025.10.031_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jaci.2018.04.041","article-title":"Accidental food allergy reactions: products and undeclared ingredients","volume":"142","author":"Blom","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.10.031_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.fct.2019.01.025","article-title":"Sensitivity analysis to derive a food consumption point estimate for deterministic food allergy risk assessment","volume":"125","author":"Blom","year":"2019","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.jaci.2025.10.031_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2022.113381","article-title":"Updated full range of eliciting dose values for cow's milk for use in food allergen risk assessment","volume":"168","author":"Blom","year":"2022","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.jaci.2025.10.031_bib11","article-title":"IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria","volume":"5","author":"Ensina","year":"2024","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaci.2025.10.031_bib12","doi-asserted-by":"crossref","DOI":"10.1089\/derm.2025.0089","article-title":"Both extrinsic and intrinsic atopy in chronic spontaneous urticaria patients indicate a favorable response to omalizumab treatment [e-pub ahead of print]","author":"Chen","year":"2025","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2025.10.031_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5021\/ad.24.004","article-title":"Biomarkers for short-term omalizumab response in chronic spontaneous urticaria","volume":"36","author":"Kim","year":"2024","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaci.2025.10.031_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2500\/aap.2024.45.230092","article-title":"Total IgE as a biomarker of omalizumab response in chronic spontaneous urticaria: a meta-analysis","volume":"45","author":"Keller","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2025.10.031_bib15","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1159\/000525723","article-title":"Discontinuing omalizumab treatment in super-responder patients with allergic severe asthma: can the baseline total IgE level be used as a biological marker to decide discontinuing omalizumab treatment?","volume":"183","author":"Arslan","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2025.10.031_bib16","series-title":"Efficacy of eight-week omalizumab monotherapy in the desensitization of multi-food allergic patients. Allergy","first-page":"45","volume":"111","author":"Long","year":"2021"},{"key":"10.1016\/j.jaci.2025.10.031_bib17","article-title":"Four-week IgE\/baseline IgE ratio combined with tryptase predicts clinical outcome in omalizumab-treated children with moderate-to-severe asthma","volume":"20","author":"Lu","year":"2025","journal-title":"Open Med (Wars)"},{"key":"10.1016\/j.jaci.2025.10.031_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.62347\/KDXJ2007","article-title":"Retrospective analysis of laboratory results in 18 cases of severe asthma treated with omalizumab","volume":"13","author":"Li","year":"2024","journal-title":"Am J Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2025.10.031_bib19","article-title":"Utility of serum biomarkers in real-world practice for predicting response to omalizumab therapy in patients with chronic spontaneous urticaria","volume":"4","author":"Cain","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaci.2025.10.031_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156814","article-title":"Predictive cytokines of omalizumab in the treatment of chronic spontaneous urticaria","volume":"185","author":"Ji","year":"2025","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2025.10.031_bib21","article-title":"The association between baseline IgE level and urticaria control at six months of omalizumab treatment in chronic urticaria","volume":"379","author":"Tuncay","year":"2025","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.10.031_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1164\/rccm.202310-1730OC","article-title":"Biomarker predictors of clinical efficacy of the anti-IgE biologic omalizumab in severe asthma in adults: results of the SoMOSA study","volume":"210","author":"Djukanovic","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.10.031_bib23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.rmed.2012.07.010","article-title":"Monitoring free serum IgE in severe asthma patients treated with omalizumab","volume":"106","author":"Korn","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2025.10.031_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/17534666231170821","article-title":"Role of clinical biomarkers in predicting the effectiveness of omalizumab","volume":"17","author":"Zhang","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaci.2025.10.031_bib25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.10.031_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/030079903125002171","article-title":"Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma","volume":"19","author":"Hochhaus","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2025.10.031_bib27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pupt.2014.03.003","article-title":"Omalizumab in patients with allergic (IgE-mediated) asthma and IgE\/bodyweight combinations above those in the initially approved dosing table","volume":"28","author":"Kornmann","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2025.10.031_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaci.2025.10.031_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.10.031_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-020-00419-z","article-title":"Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy","volume":"16","author":"Langlois","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2025.10.031_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2020.08.039","article-title":"Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients","volume":"147","author":"Azzano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.10.031_bib32","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/all.15217","article-title":"Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study","volume":"77","author":"Sindher","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.10.031_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molimm.2020.03.017","article-title":"Epitopes with similar physicochemical properties contribute to cross reactivity between peanut and tree nuts","volume":"122","author":"Nesbit","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaci.2025.10.031_bib34","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1046\/j.1365-2222.2003.01761.x","article-title":"Immunological analysis of allergenic cross-reactivity between peanut and tree nuts","volume":"33","author":"de Leon","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.10.031_bib35","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstrom","year":"2019","journal-title":"Clin Exp Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925011248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925011248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:54:00Z","timestamp":1781006040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925011248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0091674925011248"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.10.031","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}